Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance

Table 1 Clinicopathological characteristics in relation to MMP9, MMP2, Type IV collagen and Macrophages immunoreactivity

Variables	N	MMP9 Positive (%)	P*	MMP2 positive (%)	P*	Type IV collagen Positive (%)	P*	Macrophages counts (M ± SD)	P**
Age (yr)
≤ 58	18	13 (72.2)	NS	9 (50.0)	NS	12 (66.7)	0.042	19.9 ± 10.6	NS
> 58	19	17 (89.5)		11 (57.9)		18 (94.7)		19.4 ± 7.3
Recurrence
No	13	10 (76.9)	NS	4 (30.8)	0.047 ^#	10 (76.9)	NS	17.3 ± 7.9	NS
Yes	24	20 (83.3)		16 (66.7)		20 (83.3)		21.0 ± 9.4
Serosa invasion
No	8	7 (87.5)	NS	4 (50)	NS	7 (87.5)	NS	12.7 ± 9.2	0.011
Yes	29	23 (79.3)		16 (55.2)		23 (79.3)		21.6 ± 8.0
Lymph node metastasis
No	10	8 (80.0)	NS	3 (30.0)	NS	10 (100)	NS	16.3 ± 8.3	NS
Yes	27	22 (81.5)		17 (63.0)		20 (74.1)		20.9 ± 9.0
Distant Metastasis
M0	29	23 (79.3)	NS	13 (44.8)	0.048	25 (86.2)	NS	18.9 ± 8.3	0.09
M1	8	7 (87.5)		7 (87.5)		5 (62.5)		22.6 ± 11.0
TNM Stage
Early	11	9 (81.8)	NS	3 (27.3)	NS	10 (90.9)	NS	12.8 ± 7.1	0.001
Advanced	26	21 (80.8)		17 (65.4)		20 (76.9)		22.6 ± 8.1

* Fisher's exact test (two-tailed), bold face representing significant data (P < 0.05), NS: No statistically significant.
** t-test (two-tailed), bold face representing significant data (P < 0.05), NS: No statistically significant.
# The differences of MMP2 expression among different recurrence area (distant recurrence, local recurrence and ovarian recurrence) are statistically significant, too (P = 0.024).

ISSN: 1479-5876